Keywords: sb, drops, development, idoxifene, osteoporosis, after, consultation
SB drops development of idoxifene in osteoporosis
Article | 21 April 1999
After consultation with the US Food and Drug Administration, SmithKlineBeecham has opted to abandon development of its selective estrogen receptor ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
